Here are the DEF 14A proxy statements from Humacyte, Inc. Warrant (HUMAW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow HUMAW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HUMAW filings page.
Humacyte, Inc. is asking stockholders at its virtual annual meeting on June 9, 2026 to approve six items, including electing three Class II directors and an advisory vote on executive pay and its frequency. Stockholders will also vote on ratifying PricewaterhouseCoopers LLP as auditor for 2026 and increasing authorized common stock from 350,000,000 to 550,000,000 shares via a charter amendment. Shares outstanding were 222,019,108 as of April 23, 2026, the record date. The proxy outlines governance practices, committee structures, and 2025 compensation, including bonuses paid at 80% of target and significant stock option and RSU grants to senior executives.